Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Who should avoid taking viral drug Mounjaro? Expert explains

Eli Lilly's recent launch of Mounjaro (tirzepatide) in India has sparked significant interest especially among those looking for weight loss and diabetes control.

The Times of India

European committee says Lilly Alzheimer's drug shouldn't get marketing approval

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling

The Independent UK

EU regulators block new Alzheimer’s drug citing potentially fatal side effects

The company behind the drug donanemab said it will ask regulators to reconsider the decision.

Euronews

From analysis to the latest developments in health,
read the most diverse news in one place.

Tariff treatment: Six diagnoses for EU pharma sector amid US trade war

Potential US tariffs on pharmaceuticals could set off a ripple effect that extends far beyond the immediate price hikes, as both the US and Europe heavily rely on each other.

Euronews

Price Targets Show These 3 Stocks Near the $1 Trillion Mark

See what analysts' price targets say about the prospects of these three stocks flirting with the $1 trillion valuation mark.

MarketBeat

How Diabetes Patients Are Fighting for Affordable Insulin

The World Health Organization states that there were around 830 million people living with diabetes in 2022. More than half of them weren't taking diabetes medications, including insulin, likely due to access and cost issues.

inkl

Mounjaro: As Eli Lilly's blockbuster anti-obesity drug comes to India, expert lists key side effects

Eli Lilly's blockbuster drug 'Mounjaro' was launched in India on Thursday. The pharma manufacturer said it has launched a first-of-its-kind medication for obesity and type 2 diabetes in the country after obtaining approval from the Central Drugs Standard Control Organisation (CDSCO). The company said it has introduced Mounjaro in a…

The Times of India

Read news from The Economist, FT, and more,
with one subscription

Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off?

Amgen is hoping to rival Novo Nordisk and Eli Lilly in the weight-loss drug market.

Barchart

Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors

Pharma giant Eli Lilly announced plans to make a massive investment in the United States. What does this and another big announcement mean for Lilly?

MarketBeat

Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance

The Independent UK

Is Johnson & Johnson Stock Underperforming the Dow?

Despite Johnson & Johnson’s underperformance relative to the Dow over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

Is Eli Lilly Stock Outperforming the Nasdaq?

Eli Lilly has outperformed the Nasdaq over the past year, and analysts are highly optimistic about the stock’s prospects.

Barchart

Is This Penny Stock’s 525% Upside Potential an Attainable Goal?

Skye Bioscience is trying to establish a presence in the weight-loss drug market.

Barchart

3 Pharmaceutical Stocks Betting Big on Weight Loss Drugs

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, pharmaceutical giants like Eli Lilly and Company (LLY), Novo Nordisk (NVO), and Amgen (AMGN) are betting big on next-generation weight loss treatments to dominate this booming market. Keeping reading.

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Weight-loss drug Zepbound helped Ireland ship $76bn in goods to the U.S.

Ireland's pharmaceutical industry shipped billions' worth of goods to the U.S., but face threats from Trump 2.0.

MarketBeat

Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial

Eli Lilly is still seeing rapid sales growth for its diabetes and weight loss drugs. However, one drug waiting in the wings hopes to be its next blockbuster.

MarketBeat

These Stocks Missed on Earnings, But Will Rebound Next Quarter

Here are three stocks from companies that missed on earnings but have strong support from analysts that makes each stock a solid Buy for the next year

Barchart

What Are Wall Street Analysts' Target Price for Eli Lilly Stock?

As Eli Lilly has outperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

Kiplinger

Eli Lilly Stock Rises After Profit, Outlook Top Expectations

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 guidance. Here's what you need to know.

The Independent UK

Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast

Barchart

Stocks Rise Before the Open With Focus on U.S. Economic Data and Amazon Earnings

March S&P 500 E-Mini futures (ESH25) are up +0.20%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.10% this morning, suggesting Wall Street is set to extend yesterday’s gains, while investors awaited a new round of U.S. economic data, remarks from Federal Reserve officials, and an earnings report from…

Barchart

Stocks Muted Before the Open With Focus on U.S. Economic Data and Amazon Earnings

March S&P 500 E-Mini futures (ESH25) are up +0.05%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.08% this morning as investors awaited a new round of U.S. economic data, remarks from Federal Reserve officials, and an earnings report from “Magnificent Seven” member Amazon.

Fortune

The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Fortune

Investors grow anxious at Novo Nordisk's silence over CagriSema weight loss results

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Fortune

Apple, Nvidia, and more of the 2025 World's Most Admired Companies

Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.

1 … 14 15 16 17

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the European Commission

the World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.